Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241074 | 0.80 | MAPK1 (0.54) | MAPK1HPGDAHRBRD4CREBBP | |
| SCHEMBL518700 | 0.77 | L3MBTL1 (0.41) | HPGDHSD17B10CYP2B6CYP11B1CYP11B2 | |
| SCHEMBL30915985 | 0.74 | MAOA (0.48) | MAPK1ALOX15 | |
| SCHEMBL569963 | 0.71 | SIGMAR1 (0.48) | HPGDHSD17B10CYP2B6 | |
| SCHEMBL2849413 | 0.70 | MAOA (0.53) | MAPK1HPGDAHRBRD4CREBBP | |
| SCHEMBL14433009 | 0.70 | MAPK1 (0.47) | MAPK1HPGDAHRBRD4CREBBP | |
| SCHEMBL8411629 | 0.70 | SIGMAR1 (0.47) | HPGDHSD17B10CYP2B6 | |
| SCHEMBL9090858 | 0.70 | SIGMAR1 (0.47) | HPGDHSD17B10CYP2B6 | |
| SCHEMBL2818152 | 0.69 | MAPK1 (0.63) | MAPK1HPGDAHRBRD4CREBBP | |
| SCHEMBL30797996 | 0.68 | CHRM3 (0.33) | CYP2B6CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105118-A1 | Tricyclic quinazolinediones | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1288216-A1 | TRICYCLIC QUINAZOLINEDIONES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105118-A1 | Tricyclic quinazolinediones | PARP1, PARP11, PARP2 | MAPK1 1694/4885HPGD 267/4885AHR 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.